Current evidence on the anticancer potential of chios mastic gum

Nutrition and Cancer

Volumn 63, Issue 8, 2011, Pages 1174-1184

  Giaginis, Constantinos ^a,b   Theocharis, Stamatios ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b UNIVERSITY OF THE AEGEAN   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

24 ISOMASTICADIENOLIC ACID; 24 ISOMASTICADIENONIC ACID; 24 MASTICADIENOLIC ACID; 24 MASTICADIENONIC ACID; ANTINEOPLASTIC AGENT; BARDOXOLONE; BETULIC ACID; CHIOS MASTIC GUM; CUCURBITACIN; CUCURBITACIN B; DAMMARADIENONE; DOXORUBICIN; GEMCITABINE; HERBACEOUS AGENT; MORONIC ACID; OLEANOLIC ACID; OLEANONIC ACID; SOYASAPONIN I; TIRUCALLOL; TRITERPENOID; UNCLASSIFIED DRUG; URSOLIC ACID; URSONIC ACID;

ANTINEOPLASTIC ACTIVITY; CHEMICAL COMPOSITION; DRUG POTENTIATION; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; MOLECULAR MECHANICS; NONHUMAN; PISTACIA LENTISCUS; REVIEW;

ANIMALS; ANTICARCINOGENIC AGENTS; HUMANS; PISTACIA; PLANT EXTRACTS; PLANT OILS; RESINS, PLANT; TRITERPENES;

EID: 84857348245     PISSN: 01635581     EISSN: 15327914     Source Type: Journal    
DOI: 10.1080/01635581.2011.607546     Document Type: Review

References (77)

1. Mills JS and White R: Natural resins of art and archaeology: their sources, chemistry and identification. Stud Conserv 22, 12-31, 1977.
2. Duke JA: Medical Plants of the Bible. Conch Publishers, New York, p. 118, 1983.
3. Mills J and White R: The identity of the resins from the Late Bronze Age shipwreck at Ulu Burum (Kas). Archaeometry 31, 37-44, 1989.
4. DalbyA: Food in the AncientWorld. FromA to Z. Taylor and Francis Group, London, UK, 2003.
5. Grieve M: A Modern Herbal, CG Leyel (Ed.): Tiger, London, UK, 1994.
6. Serpico M: Resins, Amber and Bitumen in Ancient Egyptian Materials and Technology, Nicholson PT and Shaw I (Eds.). Cambridge, UK, Cambridge University Press, pp. 430-474, 2000.
7. Al-Habbal MJ, Al-Habbal Z, and Huwez FU: A double-blind controlled clinical trial of mastic and placebo in the treatment of duodenal ulcer. Clin Exp Pharmacol Physiol 11, 541-544, 1984. (Pubitemid 15190343)
8. Al-Said MS, Ageel AM, Parmar NS, and Tariq M: Evaluation of mastic, a crude drug obtained from Pistacia lentiscus for gastric and duodenal anti-ulcer activity. J Ethnopharmacol 15, 271-278, 1986. (Pubitemid 16082456)
9. Huwez FU and Al-HabbalMJ: Mastic in treatment of benign gastric ulcers. Gastroenterol Jpn 21, 273-241, 1986.
10. Iauk L, Ragusa S, Rapisarda A, Franco S, and Nicolosi VM: In vitro antimicrobial activity of Pistacia lentiscus L. extracts: preliminary report. J Chemother 8, 207-209, 1996. (Pubitemid 26202906)
11. Koutsoudaki C, Krsek M, and Rodger A: Chemical composition and antibacterial activity of the essential oil and the gum of Pistacia lentiscus Var. chia. J Agric Food Chem 53, 7681-7685, 2005. (Pubitemid 41499608)
12. Sterer N: Antimicrobial effect of mastic gum methanolic extract against Porphyromonas gingivalis. J Med Food 9, 290-292, 2006. (Pubitemid 44036124)
13. Paraschos S, Magiatis P, Mitakou S, Petraki K, Kalliaropoulos A, et al.: In vitro and in vivo activities of Chios mastic gum extracts and constituents against Helicobacter pylori. Antimicrob Agents Chemother 51, 551-559, 2007. (Pubitemid 46185272)
14. Janakat S and Al-Merie H: Evaluation of hepatoprotective effect of Pistacia lentiscus, Phillyrea latifolia, and Nicotiana glauca. J Ethnopharmacol 83, 135-138, 2002. (Pubitemid 36164737)
15. Ljubuncic P, Song H, Cogan U, Azaizeh H, and Bomzon A: The effect of aqueous extracts prepared from the leaves of Pistacia lentiscus in experimental liver disease. J Ethnopharmacol 100, 198-204, 2005. (Pubitemid 41073546)
16. Triantafyllou A, Chaviaras N, Sergentanis TN, Protopapa E, and Tsaknis J: Chios mastic gum modulates serum biochemical parameters in a human population. J Ethnopharmacol 111, 43-49, 2007. (Pubitemid 46482880)
17. Andrikopoulos NK, Kaliora AC,Assimopoulou AN, and Papapeorgiou VP: Biological activity of some naturally occurring resins, gums and pigments against in vitro LDL oxidation. Phytother Res 17, 501-507, 2003. (Pubitemid 36605902)
18. Dedoussis GV, Kaliora AC, Psarras S, Chiou A, Mylona A, et al.: Antiatherogenic effect of Pistacia lentiscus via GSH restoration and downregulation of CD36 mRNA expression. Atherosclerosis 174, 293-303, 2004. (Pubitemid 38597086)
19. Assimopoulou AN, Zlatanos SN, and Papageorgiou VP: Antioxidant activity of natural resins and bioactive triterpenes in oil substrates. Food Chem 92, 721-727, 2005. (Pubitemid 40544817)
20. Zhou L, Satoh K, Takahashi K, Watanabe S, Nakamura W, et al.: Re-evaluation of antiinflammatory activity of mastic using activated macrophages. In Vivo 23, 583-589, 2009.
21. Kim HJ and Neophytou C: Natural antiinflammatory compounds for the management and adjuvant therapy of inflammatory bowel disease and its drug delivery system. Arch Pharm Res 32, 997-1004, 2009.
22. Loizou S, Paraschos S, Mitakou S, Chrousos GP, Lekakis I, et al.: Chios mastic gum extract and isolated phytosterol tirucallol exhibit anti-inflammatory activity in human aortic endothelial cells. Exp BiolMed (Maywood) 234, 553-561, 2009.
23. Orhan I, Küpeli E, Aslan M, Kartal M, and Yesilada E: Bioassay-guided evaluation of antiinflammatory and antinociceptive activities of pistachio, Pistacia vera L. J Ethnopharmacol 105, 235-240, 2006.
24. Aksoy A, Duran N, Toroglu S, and Koksal F: Short-term effect of mastic gum on salivary concentrations of cariogenic bacteria in orthodontic patients. Angle Orthod 77, 124-128, 2007.
25. Takahashi K, Fukazawa M, Motohira H, Ochiai K, Nishikawa H, et al.: A pilot study on antiplaque effects of mastic chewing gum in the oral cavity. J Periodontol 74, 501-505, 2003. (Pubitemid 36553388)
26. Kaliora AC, Stathopoulou MG, Triantafillidis JK, Dedoussis GV, and Andrikopoulos NK: Alterations in the function of circulating mononuclear cells derived from patients with Crohn's disease treated with mastic. World J Gastroenterol 13, 6031-6036, 2007. (Pubitemid 350238271)
27. Kaliora AC, Stathopoulou MG, Triantafillidis JK, Dedoussis GV, and Andrikopoulos NK: Chios mastic treatment of patients with active Crohn's disease. World J Gastroenterol 13, 748-753, 2007.
28. Papageorgiou VP, Mellidis A-S, and Argyriadou N: The chemical composition of the essential oil of mastic gum. J Essent Oil Res 3, 107-110, 1991.
29. Magiatis P, Melliou E, Skaltsounis AL, Chinou IB, and Mitaku S: Chemical composition and antimicrobial activity of the essential oils of Pistacia lentiscus var. chia. Planta Med 65, 749-752, 1999.
30. Tsokou A, Georgopoulou K, Melliou E, Magiatis P, and Tsitsa E: Composition and enantiomeric analysis of the essential oil of the fruits and the leaves of Pistacia vera from Greece. Molecules 12, 1233-1239, 2007.
31. Kaliora AC, Milona A, Chiou A, Petsios DG, and Andrikopoulos NK: Detection and identification of simple phenolics in Pistacia lentiscus resin. J Liq Chromatogr Relat Technol 27, 289-300, 2004. (Pubitemid 38294977)
32. Papageorgiou VP, Bakola-Christianopoulou MN, Apazidou KK, and Psarros EE: Gas chromatographic analysis of the acidic triterpenic fraction of mastic gum. J Chromatogr 769, 262-273, 1997.
33. He ML, Li A, Xu CS, Wang SL, Zhang MJ, et al.: Mechanisms of antiprostate cancer by gum mastic: NF-kappaB signal as target. Acta Pharmacol Sin 28, 446-452, 2007.
34. He ML, Chen WW, Zhang PJ, Jiang AL, Fan W, et al.: Gum mastic increases maspin expression in prostate cancer cells. Acta Pharmacol Sin 28, 567-572, 2007. (Pubitemid 46496086)
35. He ML, Yuan HQ, Jiang AL, Gong AY, Chen WW, et al.: Gum mastic inhibits the expression and function of the androgen receptor in prostate cancer cells. Cancer 106, 2547-2555, 2006.
36. Moulos P, Papadodima O, Chatziioannou A, Loutrari H, Roussos C, et al.: A transcriptomic computational analysis of mastic oil-treated Lewis lung carcinomas reveals molecular mechanisms targeting tumor cell growth and survival. BMC Med Genomics 2, 68, 2009.
37. Magkouta S, Stathopoulos GT, Psallidas I, Papapetropoulos A, Kolisis FN, et al.: Protective effects of mastic oil from Pistacia lentiscus variation chia against experimental growth of lewis lung carcinoma. Nutr Cancer 61, 640-648, 2009.
38. Balan KV, Demetzos C, Prince J, Dimas K, Cladaras M, et al.: Induction of apoptosis in human colon cancer HCT116 cells treated with an extract of the plant product, Chios mastic gum. In Vivo 19, 93-102, 2005. (Pubitemid 40450382)
39. Balan KV, Prince J, Han Z, Dimas K, Cladaras M, et al.: Antiproliferative activity and induction of apoptosis in human colon cancer cells treated in vitro with constituents of a product derived from Pistacia lentiscus L. var. chia. Phytomedicine 14, 263-272, 2007. (Pubitemid 46386393)
40. DimasK, Hatziantoniou S,Wyche JH, and Pantazis P: Amastic gum extract induces suppression of growth of human colorectal tumor xenografts in immunodeficient mice. In Vivo 23, 63-68, 2009.
41. Loutrari H, Magkouta S, Pyriochou A, Koika V, Kolisis FN, et al.: Mastic oil from Pistacia lentiscus var. chia inhibits growth and survival of human K562 leukemia cells and attenuates angiogenesis. Nutr Cancer 55, 86-93, 2006. (Pubitemid 44477049)
42. Sakagami H, KishinoK,KobayashiM,Hashimoto K, Iida S, et al.: Selective antibacterial and apoptosis-modulating activities of mastic. In Vivo 23, 215-223, 2009.
43. Huang XY,Wang HC, Yuan Z, Li A, HeML, et al.: Gemcitabine combined with gum mastic causes potent growth inhibition and apoptosis of pancreatic cancer cells. Acta Pharmacol Sin 31, 741-745, 2010.
44. Chávez IO, Apan TR, and Martínez-Vázquez M: Cytotoxic activity and effect on nitric oxide production of tirucallane-type triterpenes. J Pharm Pharmacol 57, 1087-1091, 2005. (Pubitemid 41391767)
45. Phongmaykin J, Kumamoto T, Ishikawa T, Suttisri R, and Saifah E: A new sesquiterpene and other terpenoid constituents of Chisocheton pendulifloru. Arch Pharm Res 31, 21-27, 2008.
46. Ruch RJ and Sigler K: Growth inhibition of rat liver epithelial tumor cells by monoterpenes does not involved Ras plasma membrane association. Carcinogenesis 15, 787-789, 1994. (Pubitemid 24124431)
47. Mitíc-Culafíc D, Zegura B, Nikolíc B, Vukovíc-Gacíc B, Knezevíc- Vukcevíc J, et al.: Protective effect of linalool, myrcene and eucalyptol against t-butyl hydroperoxide induced genotoxicity in bacteria and cultured human cells. Food Chem Toxicol 47, 260-266, 2009.
48. Nguyen AT, Fontaine J, Malonne H, Claeys M, Luhmer M, et al.: A sugar ester and an iridoid glycoside from Scrophularia ningpoensis. Phytochemistry 66, 1186-1191, 2005. (Pubitemid 40728316)
49. Yan SL, Huang CY, Wu ST, and Yin MC: Oleanolic acid and ursolic acid induce apoptosis in four human liver cancer cell lines. Toxicol In Vitro 24, 842-848, 2010.
50. Yeh CT, Wu CH, and Yen GC: Ursolic acid, a naturally occurring triterpenoid, suppresses migration and invasion of human breast cancer cells by modulating c-Jun N-terminal kinase, Akt and mammalian target of rapamycin signaling. Mol Nutr Food Res 54, 1285-1295, 2010.
51. Chiang YM, Chang JY, Kuo CC, Chang CY, and Kuo YH: Cytotoxic triterpenes from the aerial roots of Ficus microcarpa. Phytochemistry 66, 495-501, 2005.
52. Ovesná Z, Vachálková A, Horváthová K, andTóthová D: Pentacyclic triterpenoic acids: new chemoprotective compounds. Minireview. Neoplasma 51, 327-333, 2004. (Pubitemid 39486104)
53. Ovesná Z, Kozics K, and Slamenová D: Protective effects of ursolic acid and oleanolic acid in leukemic cells. Mutat Res 600, 131-137, 2006.
54. Ramos AA, Pereira-Wilson C, and Collins AR: Protective effects of ursolic acid and luteolin against oxidative DNA damage include enhancement of DNA repair in Caco-2 cells. Mutat Res 692, 6-11, 2010.
55. Zhang Y, Kong C, Zeng Y,Wang L, Li Z, et al.: Ursolic acid induces PC-3 cell apoptosis via activation of JNK and inhibition of Akt pathways in vitro. Mol Carcinog 49, 374-385, 2010.
56. Huang Z, Zhang Y, Zhao L, Jing Y, Lai Y, et al.: Synthesis and antihuman hepatocellular carcinoma activity of new nitric oxide-releasing glycosyl derivatives of oleanolic acid. Org Biomol Chem 8, 632-639, 2010.
57. Liby KT, Yore MM, and Sporn MB: Triterpenoids and rexinoids as multifunctional agents for the prevention and treatment of cancer. Nat Rev Cancer 7, 357-369, 2007. (Pubitemid 46652485)
58. SetzerWNand Setzer MC: Plant-derived triterpenoids as potential antineoplastic agents. Mini Rev Med Chem 3, 540-556, 2003.
59. Kress CL, Konopleva M, Martínez-García V, Krajewska M, Lefebvre S, et al.: Triterpenoids display single agent anti-tumor activity in a transgenic mousemodel of chronic lymphocytic leukemia and small B cell lymphoma. PloS One 2, e559, 2007.
60. Sun SY: Therapeutic potential of synthetic triterpenoids in neuroblastoma. Cancer Biol Ther 7, 718-720, 2008.
61. Petronelli A, Pannitteri G, Testa U: Triterpenoids as new promising anticancer drugs. Anticancer Drugs 20, 880-892, 2009.
62. Gao X, Deeb D, Hao J, Liu Y, Arbab AS, et al.: Synthetic triterpenoids inhibit growth, induce apoptosis and suppress pro-survival Akt, mTOR and NF-{kappa}B signaling proteins in colorectal cancer cells. Anticancer Res 30, 785-792, 2010.
63. Hyer ML, Shi R, Krajewska M, Meyer C, Lebedeva IV, et al.: Apoptotic activity and mechanism of 2-cyano-3,12-dioxoolean-1,9-dien-28-oicacid and related synthetic triterpenoids in prostate cancer. Cancer Res 68, 2927-2933, 2008. (Pubitemid 351556293)
64. Petronelli A, Saulle E, Pasquini L, Petrucci E, Mariani G, et al.: High sensitivity of ovarian cancer cells to the synthetic triterpenoid CDDOimidazolide. Cancer Lett 282, 214-228, 2009.
65. Deeb D, Gao X, Jiang H, Janic B, Arbab AS, et al.: Oleanane triterpenoid CDDO-Me inhibits growth and induces apoptosis in prostate cancer cells through a ROS-dependent mechanism. Biochem Pharmacol 79, 350-360, 2010.
66. Alabran JL, Cheuk A, Liby K, Sporn M, Khan J, et al.: Human neuroblastoma cells rapidly enter cell cycle arrest and apoptosis following exposure to C-28 derivatives of the synthetic triterpenoid CDDO. Cancer Biol Ther 7, 709-717, 2008.
67. Gao X, Deeb D, Jiang H, Liu Y, Dulchavsky SA, et al.: Synthetic triterpenoids inhibit growth and induce apoptosis in human glioblastoma and neuroblastoma cells through inhibition of prosurvival Akt, NF-kappaB and Notch1 signaling. J Neurooncol 84, 147-157, 2007. (Pubitemid 47202123)
68. Sogno I, Vannini N, Lorusso G, Cammarota R, Noonan DM, et al.: Antiangiogenic activity of a novel class of chemopreventive compounds: oleanic acid terpenoids. Recent Results Cancer Res 181, 209-212, 2009.
69. Pang X, Zhang L,Wu Y, Lin L, Li J, et al.:Methyl 2-cyano-3,11-dioxo-18- olean-1,12-dien-30-oate, a derivative of glycyrrhetinic acid, functions as a potent angiogenesis inhibitor. J Pharmacol Exp Ther 335, 172-179, 2010.
70. Lee DH, Iwanski GB, and Thoennissen NH: Cucurbitacin: ancient compound shedding new light on cancer treatment. ScientWorld J 10, 413-418, 2010.
71. Iwanski GB, Lee DH, En-Gal S, Doan NB, Castor B, et al.: Cucurbitacin B, a novel in vivo potentiator of gemcitabine with low toxicity in the treatment of pancreatic cancer. Br J Pharmacol 160, 998-1007, 2010.
72. Chen W, Leiter A, Yin D, Meiring M, Louw VJ, et al.: Cucurbitacin B inhibits growth, arrests the cell cycle, and potentiates antiproliferative efficacy of cisplatin in cutaneous squamous cell carcinoma cell lines. Int J Oncol 37, 737-743, 2010.
73. Zhang W and Popovich DG: Chemical and biological characterization of oleanane triterpenoids from soy. Molecules 14, 2959-2975, 2009.
74. Ling H, Zhang Y, Ng KY, and Chew EH: Pachymic acid impairs breast cancer cell invasion by suppressing nuclear factor-kappaB-dependent matrix metalloproteinase-9 expression. Breast Cancer Res Treat, in press.
75. Hsum YW, Yew WT, Hong PL, Soo KK, Hoon LS, et al.: Cancer chemopreventive activity of maslinic acid: suppression of COX-2 expression and inhibition of NF-kappaB and ap-1 activation in Raji cells. Planta Med, in press.
76. Salminen A, Lehtonen M, Suuronen T, Kaarniranta K, and Huuskonen J: Terpenoids: natural inhibitors of NF-kappaB signaling with antiinflammatoy and anticancer potential. Cell Mol Life Sci 65, 2979-2999, 2008.
77. Eiznhamer DA and Xu ZQ: Betulinic acid: a promising anticancer candidate. IDrugs 7, 359-373, 2004.